Advertisement Carrington subsidiary secures antigen for vaccine trial - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Carrington subsidiary secures antigen for vaccine trial

Carrington Laboratories has said its subsidiary, DelSite Biotechnologies, has secured a source of influenza antigen for a phase I trial of a nasal powder influenza vaccine based on its GelVac dry powder technology.

“The acquisition of a GLP and cGMP antigen relieves us of the expense of producing an antigen using our viral and cell banks. Thus, we can invest these funds toward the needs for the phase I trial,” said Carlton Turner, CEO of Carrington.

The GelVac powder contains the in situ gelling GelSite polymer that is manufactured by DelSite. This vaccine provides distinct potential advantages in the event of a pandemic, including room temperature stability, prolonged shelf life, distribution without refrigeration, and needle-free administration.

According to DelSite, the GelVac system requires no organic solvent in the manufacturing process, uses no preservatives, and does not require refrigeration. It also gels in situ and is mucoadhesive, providing prolonged nasal residence time and thus increasing antigen delivery. Additionally both systemic and mucosal immunity are induced with nasal immunization.

Toxicology study protocols relevant to this vaccine are being reviewed at the FDA. Pending successful toxicological studies, this will be the first influenza nasal powder vaccine to be used in a human clinical trial.